Related Experiment Video
Updated: May 5, 2026
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
2.3K
Selecting patients for KIT inhibition in melanoma
Richard D Carvajal1, Omid Hamid, Cristina R Antonescu
1Melanoma/Sarcoma Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Methods in Molecular Biology (Clifton, N.J.)
|November 22, 2013
Summary
Targeted therapies for melanoma are advancing due to molecular insights. This chapter focuses on KIT alterations in melanoma, discussing KIT inhibition and patient selection for effective treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Melanoma was historically treated as a single entity.
- Recent molecular discoveries have redefined melanoma management, improving outcomes.
- Identifying key molecular alterations is crucial for targeted therapies.
Purpose of the Study:
- To explore the role of KIT alterations in melanoma.
- To review the clinical data and rationale for KIT inhibition.
- To provide guidelines for patient selection and laboratory assessment of KIT.
Main Methods:
- Review of biological mechanisms of KIT in melanoma.
- Analysis of clinical data for KIT inhibitor therapies.
- Discussion of laboratory methods for KIT assessment.
Main Results:
- KIT alterations define a specific molecular subgroup of melanoma.
- KIT inhibition shows promise for patients with activating KIT alterations.
- Standardized methods for KIT assessment are needed.
Conclusions:
- Understanding molecular subgroups like KIT alterations is key to personalized melanoma treatment.
- KIT inhibition represents a targeted therapeutic opportunity.
- Accurate KIT assessment is essential for patient selection and treatment efficacy.
